1432056-70-6

Basic information

• Product Name: 5-benzyl-7(S)-tert-butoxycarbonylamino-5-azaspiro[2,4]heptane
• CAS NO: 1432056-70-6
• Molecular Weight: 302.417
• Mol File: 1432056-70-6.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 5-benzyl-7(S)-tert-butoxycarbonylamino-5-azaspiro[2,4]heptane(CAS DataBase Reference)
• NIST Chemistry Reference: 5-benzyl-7(S)-tert-butoxycarbonylamino-5-azaspiro[2,4]heptane(1432056-70-6)
• EPA Substance Registry System: 5-benzyl-7(S)-tert-butoxycarbonylamino-5-azaspiro[2,4]heptane(1432056-70-6)

Safety Data

• Hazardous Substances Data: 1432056-70-6(Hazardous Substances Data)

Upstream product

• 129306-07-6 5-benzyl-5-azaspiro[2.4]heptane-7-amine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 129306-05-4 ethyl 1-(2-bromoacetyl)cyclopropanecarboxylate 
• 180506-32-5 (R)-5-Benzyl-7-hydroxy-5-aza-spiro[2.4]heptan-4-one 
• 129306-04-3 5-benzyl-5-azaspiro[2.4]heptane-4,7-dione 
• 331443-52-8 N-benzyl-1-(2-bromoacetyl)cyclopropanecarboxamide 
• 147011-39-0 1-acetyl-N-[benzyl]cyclopropane-1-carboxamide 
• 882-36-0 N-benzyl-3-oxobutanamide 
• 144282-35-9 5-benzyl-7(S)-amino-5-azaspiro[2,4]heptane 
• 129306-06-5 4-oxo-5-benzyl-7-hydroxyimino-5-azaspiro[2,4]heptane 
• 129306-06-5 (7E)-5-benzyl-7-(hydroxyimino)-5-azaspiro[2.4]heptan-4-one 

Relevant articles and documents

Preparation method of sitafloxacin hydrate

The invention discloses a preparation method of sitafloxacin hydrate. The method comprises the following steps: taking ethyl 4-bromoacetoacetate used as a raw material, enabling ethyl 4-bromoacetoacetate to be fully reacted with 1,2-dibromoethane and preparing the obtained product into a compound II in the presence of carbonyl reduction enzyme; taking the compound II, enabling the compound II to carry out cyclization reaction with benzylamine in a solvent in the presence of cesium carbonate, enabling the obtained product to be reacted with DPPA and preparing a compound IV; reducing nitrine group of the compound IV to prepare a compound V; connecting primary amine group of the compound V with a BOC protection group to obtain a compound VI; reducing the compound VI through Pd/C, enabling theobtained product to be reacted with 8-chlorine-6,7-difluoro-1-[(1R,2s)-2-fluorocyclopropyl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ethyl ester to prepare a compound VIII; and carrying out deprotection of the compound VIII to obtain sitafloxacin hydrate. The sitafloxacin hydrate is few in preparation steps, simple in post-treatment and relatively high in yield.

Substituted alkynyl pyridine compounds and methods of use thereof, and use thereof

The invention provides a substituted alkynylpyridine compound with a structure represented by a formula (I) as described in the specification and a pharmaceutically acceptable salt and a medicinal preparation thereof. The compound is used for adjusting activity of protein kinase and adjusting intercellular or intracellular signal response. The invention also relates to a pharmaceutical composition including the compound provided by the invention and a method of applying the pharmaceutical composition in treating mammals, especially in treating highly proliferative diseases of the mankind.

SUBSTITUTED ALKYNYL PYRIDINE COMPOUNDS AND METHODS OF USE

The present invention provides novel substituted alkynyl pyridine compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.